58
https://pubmed.ncbi.nlm.nih.gov/38112061
This study found that the 9-valent HPV vaccine is generally well-tolerated in individuals aged 16-26 years in Chongqing, China, with most adverse reactions being mild-to-moderate vaccination-site symptoms.